skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Sorafenib for the treatment of unresectable hepatocellular carcinoma

Review

(3211) Views  (974) Full article downloads

Authors: Junji Furuse

Published Date November 2008 Volume 2008:2(4) Pages 779 - 788
DOI: http://dx.doi.org/10.2147/BTT.S3410

Junji Furuse

Department of Internal Medicine, Medical Oncology, School of Medicine, Kyorin University

Abstract: Raf kinases and vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases are potential molecular targets for obtaining both anti-tumor cell progression and anti-angiogenesis effects in cancers, including hepatocellular carcinoma (HCC). Sorafenib is an oral multi-kinase inhibitor that mainly targets Raf kinases and receptor tyrosine kinases associated with angiogenesis (VEGFR-2/-3, PDGFR-β). A global randomized controlled trial (RCT) of sorafenib versus placebo conducted in patients with advanced HCC demonstrated the beneficial effects of the drug on the time-to-progression and overall survival. Furthermore, a RCT with a similar design to that of the global trial conducted in the Asia-Pacific region also demonstrated the efficacy of the drug. The most common treatment-related adverse events of sorafenib were found to be diarrhea, fatigue, and skin toxicity, namely, hand-foot syndromes and rash. Based on the results of the RCTs, sorafenib has been established as a standard agent for systemic chemotherapy in HCC patients with metastatic disease or transcatheter arterial chemoembolization (TACE)-refractory disease who are not suitable candidates for local treatments. The efficacy and safety of sorafenib in patients with moderate liver dysfunction have not been confirmed to date and more data are needed. Development of new therapeutic methods is needed for the treatment of advanced HCC in the future; clinical trials of sorafenib-based combination therapy, second-line therapy after sorafenib failure, and adjuvant therapy after local treatments are warranted in HCC patients.

Keywords: hepatocellular carcinoma, sorafenib, raf kinase, vascular endothelial growth factor receptor, platelet-derived growth factor receptor








Readers of this article also read:

The potential role of curcumin (diferuloylmethane) in plasma cell dyscrasias/paraproteinemia
α-L-iduronidase therapy for mucopolysaccharidosis type I
Review of recombinant human deoxyribonuclease (rhDNase) in the management of patients with cystic fibrosis
Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)
Etiology of hypercoagulable state in women with recurrent fetal loss without other causes of miscarriage from Southern Italy: new clinical target for antithrombotic therapy
Therapeutic vaccines for malignant brain tumors
Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency
Abatacept in difficult-to-treat juvenile idiopathic arthritis
Periosteoplasty for covering gingival recessions: Clinical results
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed